Mental Fitness

Abu Dhabi’s Life-Sciences Ecosystem: Early Pharma Input Key

Abu Dhabi’s Life-Sciences Ecosystem: Early Pharma Input Key

Professor David Adler, Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine, highlights the importance of early pharmaceutical-development input in assessing the therapeutic potential of scientific discoveries. With over 15 years in oncology research and development, including a decade in senior leadership at Bayer, he discusses practical approaches for Abu Dhabi to leverage its life-sciences ecosystem.

Timing as a strategic advantage

Adler emphasizes that Abu Dhabi’s advantage lies in the timing of pharmaceutical-development input. Introducing development questions early allows researchers to adjust their experimental plans before significant resources are committed. For instance, while a biological mechanism may contribute to disease in a laboratory model, it doesn’t guarantee that a drug targeting the same mechanism will benefit patients. Early input from development specialists can redirect experiments toward human-sample validation or pharmacological testing, ensuring that therapeutic applications are scientifically justified.

Adler notes that Abu Dhabi’s investments in research institutions, healthcare infrastructure, genomics, and international partnerships provide a strong foundation. However, the key challenge is ensuring that individual research teams can access expertise without bureaucratic hurdles. He suggests voluntary, project-level consultations involving specialists in areas like translational pharmacology and clinical oncology. These consultations would provide focused assessments, identifying missing evidence and guiding experimental decisions, rather than serving as administrative reviews.

Bridging academia and industry

Drawing on his initiative in Israel, Adler outlines a model for integrating pharmaceutical-industry expertise into academic research. This includes a practical course on drug development, direct engagement between academic and industry scientists, and a strategic task force to evaluate discoveries. While the initiative is still in its early stages, its core functions could be adapted for Abu Dhabi, leveraging existing academic and international partnerships.

Adler suggests that researchers can identify promising discoveries by asking three questions: Is there credible evidence linking the mechanism to human disease? Is therapeutic intervention plausible? And can a specific uncertainty be resolved through experimentation? This approach focuses on generating evidence to inform decisions, rather than ranking discoveries by commercial potential. For example, a pathway associated with aggressive tumor behavior may not necessarily be a viable drug target without further testing.

Abu Dhabi’s resources in genomics, clinical data, biobanking, and clinical research can help researchers validate laboratory discoveries in human populations. Well-characterized tumor samples, linked to clinical information, can test whether a proposed mechanism is relevant to specific patient groups. However, the value lies not in the volume of data, but in its ability to challenge or strengthen therapeutic hypotheses. Researchers must also consider factors like sample quality, treatment history, and tumor heterogeneity.

Enhancing Research Translation Through Strategic Initiatives

A practical course on pharmaceutical research and development is being developed, with contributions from senior industry executives. The focus is on scientific and strategic decisions in advancing from discovery to early clinical development, rather than merely outlining drug development stages. Additionally, direct engagement opportunities between academic investigators and experienced industry scientists are being created to support collaboration. A proposed Pharma-Academic Strategic Task Force aims to evaluate selected discoveries, clarify development uncertainties, and explore relevant connections.

Distinguishing genomic data from therapeutic evidence

While population genomics reveals inherited variations, tumor sequencing identifies molecular changes. However, neither alone proves that targeting a specific mechanism will benefit patients. Functional, pharmacological, and clinical evidence are essential to establish therapeutic potential.

Measuring translational success

Adler defines meaningful success for Abu Dhabi as the emergence of innovative biotechnology companies, valuable intellectual property, and development partnerships that attract investment. Over time, he expects therapeutic candidates from Abu Dhabi’s research institutions to progress into clinical development, with some showing clinical activity in Phase II trials, ultimately leading to the development of new medicines.

Leave a Comment

Your email address will not be published. Required fields are marked *